View Financial HealthDocMorris 배당 및 자사주 매입배당 기준 점검 0/6DocMorris 배당금을 지급한 기록이 없습니다.핵심 정보0%배당 수익률-55.7%자사주 매입 수익률총 주주 수익률-55.7%미래 배당 수익률0%배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향0%최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Andrea Belliger was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Apr 17DocMorris AG, Annual General Meeting, May 12, 2026DocMorris AG, Annual General Meeting, May 12, 2026, at 17:00 W. Europe Standard Time.공시 • Oct 17+ 1 more updateDocMorris AG Reaffirms Earnings Guidance for 2025DocMorris AG confirmed the revenue and earnings guidance for 2025 communicated on 10 April.공시 • May 23DocMorris AG has completed a Follow-on Equity Offering in the amount of CHF 208.051043 million.DocMorris AG has completed a Follow-on Equity Offering in the amount of CHF 208.051043 million. Security Name: Shares Security Type: Common Stock Securities Offered: 36,182,790 Price\Range: CHF 5.75 Transaction Features: Rights Offering공시 • May 22DocMorris AG announced that it expects to receive funding from Pelion S.A.DocMorris AG announced that it will receive Funding from the new investor, Pelion S.A. for 9.68% stake in the company on May 20, 2025. The company will issue공시 • Apr 18+ 1 more updateDocMorris AG to Report First Half, 2026 Results on Aug 29, 2026DocMorris AG announced that they will report first half, 2026 results on Aug 29, 2026공시 • Apr 15DocMorris AG, Annual General Meeting, May 08, 2025DocMorris AG, Annual General Meeting, May 08, 2025, at 17:00 W. Europe Standard Time.공시 • Apr 11DocMorris AG Provides Earnings Guidance for the Year 2025DocMorris AG provided earnings guidance for the year 2025. For the year, the company expects external revenues growth of more than 10%.공시 • Jul 12+ 1 more updateDocMorris AG to Report First Half, 2025 Results on Aug 19, 2025DocMorris AG announced that they will report first half, 2025 results on Aug 19, 2025공시 • Jun 20DocMorris AG to Report Q3, 2025 Results on Oct 16, 2025DocMorris AG announced that they will report Q3, 2025 results on Oct 16, 2025New Risk • May 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-CHF115m). Share price has been volatile over the past 3 months (7.6% average weekly change). Shareholders have been diluted in the past year (8.1% increase in shares outstanding).Reported Earnings • Mar 24Full year 2023 earnings released: CHF10.07 loss per share (vs CHF15.88 loss in FY 2022)Full year 2023 results: CHF10.07 loss per share (improved from CHF15.88 loss in FY 2022). Revenue: CHF976.4m (down 39% from FY 2022). Net loss: CHF117.6m (loss narrowed 31% from FY 2022). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Consumer Retailing industry in the United Kingdom.New Risk • Mar 22New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.3% per year for the foreseeable future. Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change).공시 • Sep 22+ 1 more updateDocMorris AG, Annual General Meeting, May 02, 2024DocMorris AG, Annual General Meeting, May 02, 2024, at 17:00 Central European Standard Time. Location: Kongresshaus Zurich Zurich Switzerland지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 DOCMZ 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: DOCMZ 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장DocMorris 배당 수익률 vs 시장DOCMZ의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (DOCMZ)0%시장 하위 25% (GB)2.2%시장 상위 25% (GB)5.7%업계 평균 (Consumer Retailing)3.5%분석가 예측 (DOCMZ) (최대 3년)0%주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 DOCMZ 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 DOCMZ 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: DOCMZ UK 시장에서 주목할만한 배당금을 지급하지 않습니다.주주 현금 배당현금 흐름 범위: DOCMZ 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YGB 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/14 13:10종가2026/06/12 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스DocMorris AG는 17명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Volker BosseBaader Helvea Equity ResearchSarah RobertsBarclaysGuillaume GallandBarclays14명의 분석가 더 보기
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Andrea Belliger was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Apr 17DocMorris AG, Annual General Meeting, May 12, 2026DocMorris AG, Annual General Meeting, May 12, 2026, at 17:00 W. Europe Standard Time.
공시 • Oct 17+ 1 more updateDocMorris AG Reaffirms Earnings Guidance for 2025DocMorris AG confirmed the revenue and earnings guidance for 2025 communicated on 10 April.
공시 • May 23DocMorris AG has completed a Follow-on Equity Offering in the amount of CHF 208.051043 million.DocMorris AG has completed a Follow-on Equity Offering in the amount of CHF 208.051043 million. Security Name: Shares Security Type: Common Stock Securities Offered: 36,182,790 Price\Range: CHF 5.75 Transaction Features: Rights Offering
공시 • May 22DocMorris AG announced that it expects to receive funding from Pelion S.A.DocMorris AG announced that it will receive Funding from the new investor, Pelion S.A. for 9.68% stake in the company on May 20, 2025. The company will issue
공시 • Apr 18+ 1 more updateDocMorris AG to Report First Half, 2026 Results on Aug 29, 2026DocMorris AG announced that they will report first half, 2026 results on Aug 29, 2026
공시 • Apr 15DocMorris AG, Annual General Meeting, May 08, 2025DocMorris AG, Annual General Meeting, May 08, 2025, at 17:00 W. Europe Standard Time.
공시 • Apr 11DocMorris AG Provides Earnings Guidance for the Year 2025DocMorris AG provided earnings guidance for the year 2025. For the year, the company expects external revenues growth of more than 10%.
공시 • Jul 12+ 1 more updateDocMorris AG to Report First Half, 2025 Results on Aug 19, 2025DocMorris AG announced that they will report first half, 2025 results on Aug 19, 2025
공시 • Jun 20DocMorris AG to Report Q3, 2025 Results on Oct 16, 2025DocMorris AG announced that they will report Q3, 2025 results on Oct 16, 2025
New Risk • May 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-CHF115m). Share price has been volatile over the past 3 months (7.6% average weekly change). Shareholders have been diluted in the past year (8.1% increase in shares outstanding).
Reported Earnings • Mar 24Full year 2023 earnings released: CHF10.07 loss per share (vs CHF15.88 loss in FY 2022)Full year 2023 results: CHF10.07 loss per share (improved from CHF15.88 loss in FY 2022). Revenue: CHF976.4m (down 39% from FY 2022). Net loss: CHF117.6m (loss narrowed 31% from FY 2022). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Consumer Retailing industry in the United Kingdom.
New Risk • Mar 22New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.3% per year for the foreseeable future. Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change).
공시 • Sep 22+ 1 more updateDocMorris AG, Annual General Meeting, May 02, 2024DocMorris AG, Annual General Meeting, May 02, 2024, at 17:00 Central European Standard Time. Location: Kongresshaus Zurich Zurich Switzerland